Pioneer Israeli Biotechnology Company Established in 2004 developing novel solutions for number of major diseases. 
Amorphical has successfully developed a unique and stable form of Amorphous Calcium Carbonate (ACC), in nano-particle form (20-80 nm) employing proprietary process based on biomimicry-searching methods utilized by certain mammals. 
The unique features of ACC have demonstrated novel modes of actions that enable disease treatment in a number of conditions, as well as performance improvement of cells and organs.
ACC has a much higher solubility than crystalline calcium carbonate (CCC) at mildly acidic conditions and neutral pH (100 times higher), compared to all similar calcium products in the market including Pfizer’s and GNC’s.  
ACC consists of nanometric primary particles in the range of 20 to 80 nanometers that are slightly agglomerated.
ACC has a remarkable higher (double) calcium absorption, compared to other calcium supplement substances.
ACC has remarkable higher calcium bioavailability and higher bioactivity, which is attributed to ACC’s capability to deliver the carbonate domains as a solid nanometric buffer. 


Biotechnology

Health Care

Life Sciences

Therapeutics

AMORPHICAL

Yossi Ben

Noga Nadel Erental

Lior Reitblatt

Nira R.

Eden Ben

Dr. Hadas Sarig Rapaport

AMORPHICAL

Org chart

Teams

Similar companies